EzeCheck Healthcare Device launched in Kalahandi District

Insight Bureau: In a significant development, EzeRx HealthTech Private Limited’s flagship healthcare screening product ‘EzeCheck’ has been deployed in Nagjhari village of Sagada Panchayat under Bhawanipatna Block of Kalahandi District.

It has started a new chapter in providing instant healthcare facilities in the remote tribal regions of Odisha – vision of CM Naveen Patnaik to provide affordable and accessible healthcare facilities to the people of Odisha.

The product was procured by the Kalahandi District Administration under the MPLAD Fund of Rajya Sabha MP Sujeet Kumar. It will be deployed in all the CHCs and several PHCs of various Blocks of Kalahandi which are located in the hilly regions of the district. It can be noted that Sagada Gram Panchayat has been adopted under “Sansad Adarsh Gram Yojana (SAGY)” by MP Sujeet Kumar.

Along with Sujeet Kumar, Lanjigarh MLA Pradip Kumar Dishari, Project Director, DRDA, Somesh Upadhyay, IAS, CDMO, Dr. Pratap Kumar Behera, BDO, Bhawanipatna, Ms. Prita Kumar, OAS and other representatives of the Gram Panchayat graced the occasion.

Support Independent Journalism? Keep us live.

The Guests stressed on the need of providing timely and adequate healthcare in the tribal regions especially women and children who are most vulnerable to Non-Communicable Diseases (NCDs) and how this product will fulfill the healthcare needs of the people. The villages of Nagjhari were encouraged for immediate checkup and get a free screening of their health.

EzeCheck is a non-invasive portable health screening device that measures Haemoglobin, Oxygen Saturation, Bilirubin, Creatinine and Random Sugar Levels instantly without a single drop of blood from the human body. This helps in detecting Anaemia and predicting Kidney, Liver and Lung problems.

EzeRx is an Odisha based MedTech Startup Company which is supported by Startup Odisha, DST, DBT, MeitY and Indian Oil Corporation.

Sujeet EzeCheck Health DeviceSujeet EzeCheck Health Device1

Comments are closed.